NEW YORK (GenomeWeb News) –Roche and Evotec today announced a three-year agreement directed at biomarker discovery for use with oncology drugs under development by Roche.
Under the terms of the deal, Evotec will use its PhosphoScout platform for the discovery of protein phosphorylation biomarkers that may be used to determine the efficacy of targeted cancer drugs in patients and for dosing decisions.
The firms will conduct multiple biomarker programs for therapeutic antibodies or small-molecule inhibitors, and Roche will conduct clinical trials and assess the development of companion diagnostics for patient stratification. Evotec will receive undisclosed upfront and milestone payments for each program.
Further details of the deal were not disclosed.
PhosphoScout is a mass spectrometry-based platform for identifying and quantifying cellular phosphorylation events. According to Evotec, it offers unbiased systems-wide profiling of signaling pathways.